{"id":"NCT03287869","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","briefTitle":"A Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Participants With Bipolar I Disorder.","officialTitle":"A Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Bipolar I Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-10-24","primaryCompletion":"2019-07-31","completion":"2019-07-31","firstPosted":"2017-09-19","resultsPosted":"2020-08-17","lastUpdate":"2020-08-17"},"enrollment":381,"design":{"allocation":null,"model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Bipolar I Disorder","Acute Mania"],"interventions":[{"type":"DRUG","name":"Brexpiprazole","otherNames":["OPC-34712"]}],"arms":[{"label":"Brexpiprazole","type":"EXPERIMENTAL"}],"summary":"This study evaluated the safety and evaluate the safety and tolerability of open-label brexpiprazole (2 - 4 mg/day, with a starting dose of 2 mg/day) for the treatment of adult subjects with bipolar I disorder. All participants received a starting dose of brexpiprazole.","primaryOutcome":{"measure":"Number of Participants With at Least One Treatment Emergent Adverse Event (TEAE) by Severity","timeFrame":"From Day 1 (after dosing) through 29 weeks (26 weeks treatment, 3 weeks safety follow-up)","effectByArm":[{"arm":"Prior Brexpiprazole","deltaMin":79,"sd":null},{"arm":"Prior Placebo","deltaMin":86,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":1},"locations":{"siteCount":73,"countries":["United States","Bulgaria","Croatia","Poland","Serbia","Ukraine"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":184},"commonTop":["Akathisia","Headache"]}}